Another Taxotere alopecia lawsuit has been filed by a cancer patient who alleges that her chemo treatment led to not temporary but permanent hair loss.

The North Carolina resident, plaintiff Gisele G., says she began her chemotherapy treatment in July 2013 and ended in December 2013. Most cancer patients go into chemotherapy aware that they will likely lose their hair from treatment. However, they generally expect that their hair will grow back. Furthermore, it has been several years since Gisele finished her chemotherapy treatment, and she says her hair has not yet grown back.

This kind of permanent hair loss, or alopecia, has been linked with certain chemotherapy drugs, including the breast cancer drug Taxotere. Gisele alleges in her Taxotere alopecia lawsuit that the drug caused permanent alopecia and disfigurement, as well as financial expenses.

Gisele filed the Taxotere alopecia lawsuit on Dec. 22, 2017 in the U.S. District Court for the Eastern District of Louisiana. The lawsuit was filed on multiple counts, including failure to warn, negligence, fraudulent misrepresentation and concealment, and fraud and deceit, among others.

Background of Taxotere

Taxotere (also known by its generic name, docetaxel) is a chemotherapy drug manufactured by pharmaceutical giant Sanofi. Taxotere was first approved by the U.S. Food and Drug Administration (FDA) back in 1996 and has remained popular throughout the two decades since.

Permanent Taxotere Hair Loss (Alopecia)

Hair loss, also known as alopecia, is an especially common symptom associated with chemotherapy treatment. While cancer patients are usually aware of the risk of hair loss during chemo, they also generally expect that after their chemotherapy treatment is eventually over their hair will grow back.

Unfortunately, many patients treated with docetaxel drugs have later found that they have significant problems growing back their hair, and others even suffer from permanent hair loss complications after chemotherapy treatment is over.

Filing a Taxotere Alopecia Lawsuit

According to this Taxotere alopecia lawsuit and others like it, Sanofi either knew or should have known that Taxotere was linked with permanent hair loss complications.

Lawsuits allege that the company not only failed to adequately warn about this risk, but even actively concealed information, instead promoting the drug as both safe and effective. Indeed, Sanofi has been aware of reports and studies linking Taxotere to permanent hair loss after chemotherapy since as far back as its approval in 1996, the lawsuits allege.

If you or someone you love has suffered from permanent hair loss after chemo treatment with Taxotere or another docetaxel medication, you may be able to seek financial compensation through a Taxotere alopecia lawsuit.

Filing a Taxotere alopecia lawsuit cannot take away the pain and suffering a cancer patient endures, or take away the effects of permanent alopecia after chemo, but it can help compensate for the financial expenses incurred by cancer treatment bills or even lost wages.

The Taxotere Alopecia Lawsuit is Case No. 2:17-cv-17709-KDE-MBN, in the U.S. District Court for the Eastern District of Louisiana.